Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K MurthySherene LoiAlicia OkinesElisavet PaplomataErika HamiltonSara A HurvitzNancy U LinVirginia BorgesVandana AbramsonCarey AndersPhilippe L BedardMafalda OliveiraErik JakobsenThomas BachelotShlomit S ShacharVolkmar MüllerSofia BragaFran Ois P DuhouxRichard GreilDavid CameronLisa A CareyGiuseppe CuriglianoKaren GelmonGabriel HortobagyiIan KropSibylle LoiblMark PegramDennis SlamonM Corinna Palanca-WesselsLuke WalkerWentao FengEric P WinerPublished in: The New England journal of medicine (2019)
In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).